Prosensa Holding NV Company Profile (NYSE:RNA)

About Prosensa Holding NV (NYSE:RNA)

Prosensa Holding NV logoProsensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company's primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. The Company's clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company's platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NYSE:RNA
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $19.00
  • 200 Day Moving Avg: $14.00
  • 52 Week Range: $4.00 - $23.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.00
  • P/E Growth: 0
  • Average Volume: 187,002 shs.

Frequently Asked Questions for Prosensa Holding NV (NYSE:RNA)

What is Prosensa Holding NV's stock symbol?

Prosensa Holding NV trades on the New York Stock Exchange (NYSE) under the ticker symbol "RNA."

How were Prosensa Holding NV's earnings last quarter?

Prosensa Holding NV (NYSE:RNA) announced its earnings results on Monday, November, 17th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.04. View Prosensa Holding NV's Earnings History.

Who are some of Prosensa Holding NV's key competitors?

How do I buy Prosensa Holding NV stock?

Shares of Prosensa Holding NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Prosensa Holding NV stock cost?

One share of Prosensa Holding NV stock can currently be purchased for approximately $19.00.

Analyst Ratings

Consensus Ratings for Prosensa Holding NV (NYSE:RNA) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Prosensa Holding NV (NYSE:RNA)
No equities research coverage for this company has been tracked by


Earnings History for Prosensa Holding NV (NYSE:RNA)
Earnings by Quarter for Prosensa Holding NV (NYSE:RNA)
Earnings History by Quarter for Prosensa Holding NV (NYSE:RNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/17/2014Q314($0.25)($0.29)$5.00 millionViewN/AView Earnings Details
8/12/2014Q214($0.36)($0.29)ViewN/AView Earnings Details
5/20/2014Q114$0.01$0.26$18.38 million$20.23 millionViewN/AView Earnings Details
3/17/2014($0.14)($0.12)$2.92 million$3.03 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Prosensa Holding NV (NYSE:RNA)
Current Year EPS Consensus Estimate: $-1 EPS
Next Year EPS Consensus Estimate: $-1 EPS


Dividend History for Prosensa Holding NV (NYSE:RNA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Prosensa Holding NV (NYSE:RNA)
No insider trades for this company have been tracked by


Headline Trends for Prosensa Holding NV (NYSE:RNA)
Latest Headlines for Prosensa Holding NV (NYSE:RNA)
DateHeadline logoBioMarin Upgraded to Strong Buy, Is It in Your Portfolio? - Analyst Blog - April 29 at 4:32 PM logoHow bubbles are blown: Biotech edition - March 31 at 7:53 AM logoBioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog - January 22 at 6:00 PM logoState Of The Union Lights Up Biotech - January 21 at 6:25 AM logoBioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst Blog - January 14 at 5:10 PM logoUS STOCKS-S&P 500 ticks up to record on central bank bets - November 24 at 4:49 PM logoUS STOCKS-Wall St up on central bank bets, deals support - November 24 at 3:19 PM logoUS STOCKS-Wall St hits new records, but telecom weighs on Dow - November 24 at 12:34 PM logoUS STOCKS-Wall St hits new records, boosted by cyclicals - November 24 at 11:18 AM logoBuying Glaxo's Biotech Stock Throwbacks Proves Profitable - November 24 at 10:57 AM logoUS STOCKS-Wall St surges to new records, boosted by cyclicals - November 24 at 10:04 AM logoBig News for Ebola Stocks - November 24 at 9:15 AM logoUS STOCKS-Futures point to higher open on merger activity - November 24 at 8:52 AM logoUS STOCKS-Futures rise, boosted by merger activity - November 24 at 8:14 AM logoBioMarin to buy Prosensa in $840 mln deal - November 24 at 6:24 AM



Prosensa Holding NV (RNA) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff